Recent Posts
- FDA Okays Blood Test for Ovarian Cancer
- Replication At DNA Damage Sites Highlights Fanconi Anemia And Breast Cancer Proteins
- ASCO To Hold Annual Meeting In Chicago For The Next Ten Years: City Seen As Best Choice To Host Meeting That Continues To Grow
- Protein Partnership Leads To Pediatric Tumor Regression
- ASCO Awarded CEO Cancer Gold Standard: Achievement Underscores Organization’s Commitment To The Health And Well-Being Of Its Employees
Random Posts
- Internists Caring For Cancer Survivors Rarely Address Sexual Problems
- FDA Approves New Treatment For Chronic Lymphocytic Leukemia
- KCA: Some Gain Against RCC with Immunomodulator (CME/CE)
- Endocyte Initiates Phase 1 Trial Of EC0489 For Treatment Of Refractory Or Metastatic Solid Tumors
- University Of Florida Scientists Use Virus To Kill Cancer Cells While Leaving Normal Cells Intact
- Fighting Cancer With Anti-Psychotic Drugs
- Tumor Suppressor Gene In Flies May Provide Insights For Human Brain Tumors
- ASCO: Ginger Eases Chemo-Related Nausea
- Green Tea: Mixed Reviews For Cancer Prevention
- ASH: Multiple Myeloma Drug Has Heavier Burden for Obese Patients (CME/CE)
Prescription Cancer Drugs
MicroRNA-Mediated Metastasis Suppression
Posted by: admin in Prescription Cancer Drugs on November 08th, 2009
Metastases are responsible for over 90% of cancer deaths. In the upcoming issue of G&D, Dr. Robert Weinberg (MIT) and colleagues lend molecular insight into how microRNAs suppress tumor metastasis.
Scott Valastyan, lead author on the study, describes it as presenting “detailed mechanistic insight regarding the process of tumor metastasis, and identifies several key regulators of this process that might prove to be interesting diagnostic and/or therapeutic targets in breast cancer.”
Dr. Weinberg’s group previously showed that the human microRNA, miR-31, suppresses breast cancer metastasis and that its expression is associated with patient outcome. miR-31 regulates the expression of almost 200 genes. However, in this new paper, the authors identify that re-introduction of three miR-31 targets is sufficient to completely reverse miR-31’s influence on metastasis.
The researchers characterized both the individual and overlapping contributions that each of these three miR-31 effectors makes to the metastatic process. While three distinct steps are affected by this cohort of miR-31 targets (namely local invasion, early post-intravasation events and metastatic colonization), of particular interest was the finding that two of the three effectors regulate metastatic colonization - the final and rate-limiting step of metastasis.
Scott Valastyan emphasizes that “Our finding that miR-31, integrin-alpha5, and radixin affect the process of metastatic colonization may be of particular interest in light of the fact that colonization efficiency is strongly associated with patient survival outcome in many human tumor types - including breast cancer”.
Source:
Heather Cosel-Pieper
Cold Spring Harbor Laboratory